title: [Advances in Bevacizumab Therapy for Non-small Cell Lung Cancer  with Brain Metastases].
abstract: Brain metastases are frequently encountered in patients with non-small cell lung cancer (NSCLC) and are a significant cause of morbidity and mortality. Antiangiogenesis therapy plays a major role in the management of brain metastases in lung cancer. Bevacizumab have become the novel method for the treatment of lung cancer with brain metastases beyond the whole brain radiation therapy, stereotactic radiosurgery and chemotherapy. Recently, more and more studies and trials laid emphasis on the bevacizumab for NSCLC with brain metastases treatment. The key point is the efficacy and safety. In this review, bevacizumab therapy of NSCLC with brain metastases were summarized.
authors: Department of Pulmonary Oncology, Shanxi Cancer Hospital, Shanxi Medical University, Taiyuan 030013, China.
authors: Liyan
authors: L
authors: Qu
authors: Department of Pulmonary Oncology, Shanxi Cancer Hospital, Shanxi Medical University, Taiyuan 030013, China.
authors: Rui
authors: R
authors: Geng
authors: Department of Pulmonary Oncology, Shanxi Cancer Hospital, Shanxi Medical University, Taiyuan 030013, China.
authors: Xia
authors: X
authors: Song
mesh_terms: D000068258:Bevacizumab / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000556:secondary*; D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology*; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology*; D009389:Neovascularization, Pathologic; D012449:Safety
chemical_list: D000068258:Bevacizumab